📣 VC round data is live. Check it out!

Solventum Valuation Multiples

Discover revenue and EBITDA valuation multiples for Solventum and similar public comparables like Medpace, Olympus, Insulet, Cooper Companies and more.

Solventum Overview

About Solventum

In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.


Founded

2023

HQ

United States

Employees

22.0K

Financials (LTM)

Revenue: $8B
EBITDA: $2B

EV

$16B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Solventum Financials

Solventum reported last 12-month revenue of $8B and EBITDA of $2B.

In the same LTM period, Solventum generated $5B in gross profit, $2B in EBITDA, and $1B in net income.

Revenue (LTM)


Solventum P&L

In the most recent fiscal year, Solventum reported revenue of $8B and EBITDA of $3B.

Solventum is profitable as of last fiscal year, with gross margin of 53%, EBITDA margin of 31%, and net margin of 19%.

See analyst estimates for Solventum
LTMLast FY202320242025202620272028
Revenue$8B$8B$8B$8B$8B
Gross Profit$5B$4B$5B$5B$4B
Gross Margin55%53%55%56%53%
EBITDA$2B$3B$2B$2B$3B
EBITDA Margin27%31%25%19%31%
EBIT Margin21%21%18%13%8%
Net Profit$1B$2B$692M$479M$2B
Net Margin13%19%8%6%19%
Net Debt$4B

Financial data powered by Morningstar, Inc.

Solventum Stock Performance

Solventum has current market cap of $12B, and enterprise value of $16B.

Market Cap Evolution


Solventum's stock price is $66.63.

Solventum share price decreased by 1.1% in the last 30 days, and by 8.8% in the last year.

Solventum has an EPS (earnings per share) of $8.97.

See more trading valuation data for Solventum
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$16B$12B0.0%-1.1%-10.2%-8.8%$8.97

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Solventum Valuation Multiples

Solventum trades at 1.9x EV/Revenue multiple, and 7.1x EV/EBITDA.

See NTM and 2027E valuation multiples for Solventum

EV / Revenue (LTM)


Solventum Financial Valuation Multiples

As of May 3, 2026, Solventum has market cap of $12B and EV of $16B.

Solventum has a P/E ratio of 10.6x.

LTMLast FY202320242025202620272028
EV/Revenue1.9x1.9x1.9x1.9x1.9x
EV/EBITDA7.1x6.2x7.7x10.3x6.2x
EV/EBIT9.2x9.2x10.6x15.2x24.9x
EV/Gross Profit3.5x3.5x3.4x3.4x3.5x
P/E10.6x7.4x16.7x24.1x7.4x
EV/FCF155.3xn/m9.7x19.5xn/m

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Solventum Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Solventum Margins & Growth Rates

Solventum decreased revenue by 2% and EBITDA by 13% in the last fiscal year.

In the most recent fiscal year, Solventum reported gross margin of 53%, EBITDA margin of 31%, and net margin of 19%.

See estimated margins and future growth rates for Solventum

Solventum Margins

Last FY202420252026202720282029
Gross Margin53%56%53%54%
EBITDA Margin31%19%31%27%
EBIT Margin21%13%8%21%
Net Margin19%6%19%14%
FCF Margin(0%)10%(0%)4%

Solventum Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(2%)0%1%(2%)
Gross Profit Growth(0%)1%(3%)(0%)
EBITDA Growth(13%)(25%)67%(13%)
EBIT Growth0%(30%)(39%)172%
Net Profit Growth(27%)(31%)225%(27%)
FCF Growth(3299%)(50%)(101%)(3299%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Solventum Operational KPIs

Solventum's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Solventum's Rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Solventum's Rule of X is 22% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Solventum
LTMLast FY202320242025202620272028
Rule of 4027%25%
Bessemer Rule of X26%22%
Revenue per Employee$0.4M
Opex per Employee$0.2M
R&D Expenses to Revenue7%9%9%9%9%
Opex to Revenue46%37%43%46%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Solventum Competitors

Solventum competitors include Medpace, Olympus, Insulet, Cooper Companies, Fresenius Medical Care, Globus Medical, Fisher & Paykel, Penumbra, Align Technology and Tempus AI.

Most Solventum public comparables operate across Health Data & Analytics, Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Medpace4.5x4.4x20.2x19.8x
Olympus1.7x1.8x7.2x11.2x
Insulet4.6x4.2x19.3x17.8x
Cooper Companies3.6x3.5x11.3x10.9x
Fresenius Medical Care1.0x1.0x5.4x5.4x
Globus Medical4.1x3.9x13.0x12.4x
Fisher & Paykel10.4x9.2x32.6x26.9x
Penumbra8.9x8.5x46.7x44.2x

This data is available for Pro users. Sign up to see all Solventum competitors and their valuation data.

Start Free Trial

Solventum Funding History

Before going public, Solventum raised $648M in total equity funding, across 1 round.


Solventum Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Aug-25Secondary - public$648M

Solventum M&A Activity

Solventum has acquired 1 company to date.

Last acquisition by Solventum was on November 20th 2025. Solventum acquired Acera Surgical for $725M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Solventum

Acera Surgical
Description
Acera Surgical is a St. Louis-based developer of resorbable synthetic scaffolds for soft tissue repair in neurosurgery and orthopedics. Its materials promote regeneration in dura mater and tendon applications, distributed to hospitals in the U.S. and Europe.
HQ CountryUnited States
HQ City
St Louis, MO
Deal Date20 Nov 2025
Valuation$725M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Solventum acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Solventum

When was Solventum founded?Solventum was founded in 2023.
Where is Solventum headquartered?Solventum is headquartered in United States.
How many employees does Solventum have?As of today, Solventum has over 22K employees.
Who is the CEO of Solventum?Solventum's CEO is Bryan C. Hanson.
Is Solventum publicly listed?Yes, Solventum is a public company listed on NYSE.
What is the stock symbol of Solventum?Solventum trades under SOLV ticker.
When did Solventum go public?Solventum went public in 2024.
Who are competitors of Solventum?Solventum main competitors include Medpace, Olympus, Insulet, Cooper Companies, Fresenius Medical Care, Globus Medical, Fisher & Paykel, Penumbra, Align Technology, Tempus AI.
What is the current market cap of Solventum?Solventum's current market cap is $12B.
What is the current revenue of Solventum?Solventum's last 12 months revenue is $8B.
What is the current revenue growth of Solventum?Solventum revenue growth (NTM/LTM) is (0%).
What is the current EV/Revenue multiple of Solventum?Current revenue multiple of Solventum is 1.9x.
Is Solventum profitable?Yes, Solventum is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Solventum?Solventum's last 12 months EBITDA is $2B.
What is Solventum's EBITDA margin?Solventum's last 12 months EBITDA margin is 27%.
What is the current EV/EBITDA multiple of Solventum?Current EBITDA multiple of Solventum is 7.1x.
What is the current FCF of Solventum?Solventum's last 12 months FCF is $101M.
What is Solventum's FCF margin?Solventum's last 12 months FCF margin is 1%.
What is the current EV/FCF multiple of Solventum?Current FCF multiple of Solventum is 155.3x.
How many companies Solventum has acquired to date?As of May 2026, Solventum has acquired 1 company.
What was the largest acquisition by Solventum?$725M acquisition of Acera Surgical on 20th November 2025 was the largest M&A Solventum has done to date.
What companies Solventum acquired?Solventum acquired Acera Surgical.
In how many companies Solventum has invested to date?Solventum hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Solventum

Lists including Solventum

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial